Cemiplimab + Chemotherapy for Sinonasal Cancer

This trial tests whether adding cemiplimab (an immunotherapy drug) to the usual chemotherapy before surgery is more effective in treating sinonasal squamous cell cancer. The researchers aim to determine if this combination can better stop the cancer from growing or spreading compared to chemotherapy alone. Participants will receive either the chemotherapy drugs carboplatin and paclitaxel or those drugs plus cemiplimab. Individuals with a confirmed diagnosis of sinonasal squamous cell carcinoma and specific tumor characteristics, without signs of cancer spreading beyond the local area, may be suitable for this study. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people, offering participants a chance to contribute to important advancements in cancer treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss your specific medications with the trial team to get a clear answer.

Research has shown that patients generally tolerate the combination of cemiplimab, carboplatin, and paclitaxel well. One study found that individuals with squamous cell carcinoma managed this combination effectively, even with other health conditions. Cemiplimab already has approval for treating certain skin cancers, indicating its well-established safety profile. Some participants experienced side effects such as tiredness and nausea, which are typical of chemotherapy. Overall, the treatment appears safe, with side effects comparable to standard chemotherapy treatments.¹²³⁴⁵

Researchers are excited about the combination of cemiplimab with chemotherapy for sinonasal cancer because cemiplimab is an immune checkpoint inhibitor, which helps the immune system better recognize and attack cancer cells. Unlike standard treatments that typically rely solely on chemotherapy, this approach aims to enhance the body's natural immune response. The addition of cemiplimab to the standard chemotherapy regimen of carboplatin and paclitaxel offers a new way to potentially improve outcomes by targeting cancer cells more precisely.

This trial will compare the effectiveness of cemiplimab combined with the chemotherapy drugs carboplatin and paclitaxel to chemotherapy alone in treating sinonasal squamous cell cancer. Research has shown that combining cemiplimab with chemotherapy can help treat certain cancers, such as head and neck cancers. Studies have found that adding cemiplimab to chemotherapy can improve outcomes, including progression-free survival. Specifically, in one study, patients who received cemiplimab with chemotherapy had a median progression-free survival of 8.2 months, compared to 5.0 months for those who had chemotherapy alone. This suggests that cemiplimab may enhance the immune system's ability to attack cancer cells, potentially leading to better control of sinonasal squamous cell cancer.⁴⁵⁶⁷⁸